Let’s talk about BiTEs and other drugs in the real-life setting for b-cell acute lymphoblastic leukemia

Deak D, Pop C, Zimta AA, Jurj A, Ghiaur A, Pasca S, Teodorescu P, Dascalescu A, Antohe I, Ionescu B, Constantinescu C, Onaciu A, Munteanu R, Berindan-Neagoe I, Petrushev B, Turcas C, Iluta S, Selicean C, Zdrenghea M, Tanase A, Danaila C, Colita A, Colita A, Dima D, Coriu D, Einsele H, Tomuleasa C (2019)

Publication Type: Journal article, Review article

Publication year: 2019

Journal

Frontiers in Immunology Frontiers Research Foundation / Frontiers Media

Book Volume: 10

Article Number: 2856

DOI: 10.3389/fimmu.2019.02856

Abstract

Background: Therapy for acute lymphoblastic leukemia (ALL) are currently initially efficient, but even if a high percentage of patients have an initial complete remission (CR), most of them relapse. Recent data shows that immunotherapy with either bispecific T-cell engagers (BiTEs) of chimeric antigen receptor (CAR) T cells can eliminate residual chemotherapy-resistant B-ALL cells. Objective: The objective of the manuscript is to present improvements in the clinical outcome for chemotherapy-resistant ALL in the real-life setting, by describing Romania’s experience with bispecific antibodies for B-cell ALL. Methods: We present the role of novel therapies for relapsed B-cell ALL, including the drugs under investigation in phase I-III clinical trials, as a potential bridge to transplant. Blinatumomab is presented in a critical review, presenting both the advantages of this drug, as well as its limitations. Results: Bispecific antibodies are discussed, describing the clinical trials that resulted in its approval by the FDA and EMA. The real-life setting for relapsed B-cell ALL is described and we present the patients treated with blinatumomab in Romania. Conclusion: In the current manuscript, we present blinatumomab as a therapeutic alternative in the bridge-to-transplant setting for refractory or relapsed ALL, to gain a better understanding of the available therapies and evidence-based data for these patients in 2019.

Involved external institutions

Iuliu Hațieganu University of Medicine and Pharmacy / Universitatea de Medicină și Farmacie "Iuliu Hațieganu" (UMF Cluj) RO Romania (RO) Spitalul Clinic Fundeni Bucuresti RO Romania (RO) Grigore T. Popa University of Medicine and Pharmacy / Universitatea de Medicină și Farmacie "Grigore T. Popa" (UMF Iași) RO Romania (RO) Coltea Clinical Hospital / Coltea Spital Clinic RO Romania (RO) Institute of Oncology Prof. Dr. Ion Chiricuta RO Romania (RO) Universitätsklinikum Würzburg DE Germany (DE)

How to cite

APA:

Deak, D., Pop, C., Zimta, A.-A., Jurj, A., Ghiaur, A., Pasca, S.,... Tomuleasa, C. (2019). Let’s talk about BiTEs and other drugs in the real-life setting for b-cell acute lymphoblastic leukemia. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.02856

MLA:

Deak, Dalma, et al. "Let’s talk about BiTEs and other drugs in the real-life setting for b-cell acute lymphoblastic leukemia." Frontiers in Immunology 10 (2019).

BibTeX: Download